BioSpace News Archive

Lifebit announces a long-term partnership where Lifebit’s technology, Lifebit CloudOS, will power a cloud-based Trusted Research Environment to serve as the scalable and secure data management and analysis platform for researchers at the National Institute for Health Research Cambridge Biomedical Research Centre.

Capricor Therapeutics announced that it has entered into a partnership with Nippon Shinyaku Co., Ltd., a Japanese pharmaceutical company listed on the TYO, for the exclusive commercialization and distribution in the United States of Capricor’s lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy, a rare neuromuscular disease with limited treatment options.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced that the first patient has been treated in its second pivotal phase III clinical trial, COMPOSE, evaluating the company’s lead radiopharmaceutical candidate, ITM-11, for the treatment of gastroenteropancreatic neuroendocrine tumors.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced an exclusive supply and technology agreement with Corning Incorporated.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, highlighted the publication of a new study that provides updated estimates of urinary incontinence prevalence in the U.S.

2021 Fourth-Quarter Sales of $24.8 Billion reflecting growth of 10.4%, operational sales growth of 11.6% and adjusted operational sales growth of 12.3%.

Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab) as reported by Johnson & Johnson were USD 6,023 million in 2021.

Matinas BioPharma Holdings, Inc. today is providing a business update on each of its ongoing programs and discussing its strategic outlook for 2022.

SwanBio Therapeutics today announced that its Investigational New Drug (IND) application for its lead candidate, SBT101, for the treatment of adrenomyeloneuropathy (AMN) was cleared by the U.S. Food and Drug Administration (FDA).

ChromaDex Corp. (NASDAQ:CDXC) today announced results of the 18th clinical trial on its flagship Niagen® (patented nicotinamide riboside, or “NR”) ingredient with promising, peer-reviewed findings reported in the Journal of Clinical Investigation.